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Background: Immediately after renal transplantation, patients experience rapid and significant improvement of
their clinical conditions and undergo considerable systemic and cellular modifications. However, some patients
present a slow recovery of the renal function commonly defined as delayed graft function (DGF). Although clinically
well characterized, the molecular mechanisms underlying this condition are not totally defined, thus, we are
currently missing specific clinical markers to predict and to make early diagnosis of this event.
Methods: We investigated, using a pathway analysis approach, the transcriptomic profile of peripheral blood
mononuclear cells (PBMC) from renal transplant recipients with DGF and with early graft function (EGF), before
(T0) and 24 hours (T24) after transplantation.
Results: Bioinformatics/statistical analysis showed that 15 pathways (8 up-regulated and 7 down-regulated) and
11 pathways (5 up-regulated and 6 down-regulated) were able to identify DGF patients at T0 and T24, respectively.
Interestingly, the most up-regulated pathway at both time points was NLS-bearing substrate import into nucleus, which
includes genes encoding for several subtypes of karyopherins, a group of proteins involved in nucleocytoplasmic
transport. Signal transducers and activators of transcription (STAT) utilize karyopherins-alpha (KPNA) for their passage
from cytoplasm into the nucleus. In vitro functional analysis demonstrated that in PBMCs of DGF patients, there was a
significant KPNA-mediated nuclear translocation of the phosphorylated form of STAT3 (pSTAT3) after short-time
stimulation (2 and 5 minutes) with interleukin-6.
Conclusions: Our study suggests the involvement, immediately before transplantation, of karyopherin-mediated
nuclear transport in the onset and development of DGF. Additionally, it reveals that karyopherins could be good
candidates as potential DGF predictive clinical biomarkers and targets for pharmacological interventions in renal
transplantation. However, because of the low number of patients analyzed and some methodological limitations,
additional studies are needed to validate and to better address these points.
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Renal transplantation is the main treatment for advanced
chronic kidney disease and it is associated with an im-
provement in the quality of life and survival of these
patients compared to dialysis treatment [1-4]. Several evi-
dences underline that immediately after transplantation,
patients experience rapid and significant changes of their
clinical conditions and undergo considerable physiological
modifications [5,6]. These changes may be primarily in-
duced by the kidney physiology reactivation, the ending of
bioincompatible dialysis stimuli (e.g. microinflammation,
oxidative stress) and the pharmacological effects following
induction therapy [7,8].
Although several therapeutic strategies have been intro-
duced to reduce early transplant complications [9-11], a
significant number of patients experience a slow recovery
of the renal function and they need to continue dialysis
treatment after transplantation. This condition is com-
monly described as delayed graft function (DGF) [12].
DGF is a multi-factorial event influenced by several factors
(e.g., kidneys from non-heart-beating donor, inotropic
support of the donor), donor characteristics (e.g., age, dia-
betes, hypertension), graft functional features as shown by
the transcriptomic profile of pre-transplant biopsy, reci-
pients conditions (e.g. pre-transplant dialysis treatment,
number of previous transplants, allosensitisation) and
length of cold ischemia time [13].
Prolonged hypothermic ischemia and subsequent reper-
fusion may activate a complex sequence of events promo-
ting renal damage and DGF. Ischemia starves tissue of
oxygen and nutrients and causes accumulation of meta-
bolic waste products [10], inhibition of oxidative metabo-
lism, ATP depletion and increase in anaerobic glycolysis
[11]. Then, in response to renal ischemia, cytoprotective
machinery is activated including rapid decrease of cel-
lular metabolic activity. Additionally, it is largely re-
ported a significant cytoprotective or regenerative genes
transcription [12]. Reinstitution of blood flow in ische-
mic kidneys causes a cascade of events, first and fore-
most the release of reactive oxygen species [12-14]. In
addition, ischemia-reperfusion injury (IRI) is character-
ized by the immune system activation, including the
local recruitment of monocyte/macrophages, granulo-
cytes and dendritic cells [15-17]. Moreover, recently our
group has demonstrated that DGF is associated with an
increased T-bet/GATA-3 ratio in graft infiltrating CD4+
T cells, suggesting the priming of a Th1 response [18].
All these events create a biological background that
makes the allograft more susceptible to develop both
acute rejection and chronic allograft nephropathy with a
consequent reduction of the graft survival [19,20].
Huge efforts have been made in the field of transplan-
tation analyzing the organ-related, donors and recipients
biological characteristics influencing DGF and to identifynovel biomarkers that enable transplant clinicians the
early identification of patients at high risk to develop
this important complication [9].
The present study, utilizing non parametric permuta-
tion tests and statistically well founded approaches for
the integrative analysis of genes and pathways assayed
with high-throughput microarray technology, has been
able to shed light on the molecular basis of DGF and to
identify a specific transcriptomic signature potentially
useful as predictive and early diagnostic biomarker in
renal transplant recipients undergoing this important
clinical complication.
Methods
Patients
In our study, we randomly selected 12 consecutive adult
first renal transplant recipients who developed DGF and 12
with early graft function (EGF). DGF was considered as the
need for dialysis within the first week of transplantation.
After enrollment, the 24 patients have been randomly
split into two groups (Table 1):
1. Training-group that included 7 patients with DGF
and 7 patients with EGF;
2. Testing-group that comprised 5 DGF and 5 EGF
patients.
DGF patients underwent a percutaneous graft biopsy to
exclude acute rejection. All patients presented low panel
reactive antibody (PRA) levels measured by Luminex.
Recipients of expanded criteria donors or having a very
high pre-transplant cold ischemia time were excluded.
Additionally, no patients included were affected by dia-
betes, chronic lung diseases, neoplasms, or inflammatory
diseases.
To avoid drug-related confounding factors all enrolled
patients received 500 mg of steroids IV and a single infu-
sion of anti-CD25 at the time of transplantation.
Biological samples were collected just before trans-
plantation (T0) and 24 hours after transplantation (T24).
The study was approved by the institutional ethical
board of the University Hospital “Policlinico di Bari”, Bari,
Italy and all patients signed an informed consent accor-
ding to the last version of the declaration of Helsinki.
Peripheral blood mononuclear cells (PBMC) isolation
Twenty ml of whole blood were harvested from all pa-
tients at the time of enrolment (T0) and 24 hours after
transplantation (T24). Peripheral blood mononuclear
cells (PBMC) were isolated by density separation over a
Ficoll-PaqueTM (GE healthcare, Uppsala, Sweden) gra-
dient (460 g for 30 min) and were washed three times
with phosphate-buffered saline (PBS) pH 7.4/1 mM
EDTA (Sigma, Milan, Italy). Cells were counted and
Table 1 Demographics and clinical characteristics of the two study groups
Demographic/clinical characteristics Training group p value Testing group p value
EGF DGF EGF DGF
Patients (n) 7 7 5 5
Gender (M/F) 4/3 3/4 n.s. 2/3 3/2 n.s.
Recipient age (years) 47.1 ± 9.3 48.3 ± 8.4 n.s. 46.3 ± 10.1 47.7 ± 7.5 n.s.
Donor age (years) 47.3 ± 9.3 51.9 ± 12.6 n.s. 49.1 ± 6.4 49.5 ± 5.9 n.s.
Donor cause of death (trauma/others) 3/4 3/4 n.s. 2/3 2/3 n.s.
HLA mismatches (n) 3.4 ± 1.2 3.5 ± 0.8 n.s. 3.4 ± 1.1 3.5 ± 0.9 n.s.
Cold ischemia time (h) 12.1 ± 3.8 17.4 ± 5.1 <0.05 11.2 ± 2.3 16.8 ± 4.3 0.01
Length of DGF (days) 0 17.8 ± 12.8 <0.001 0 14.2 ± 16.3 <0.001
EGF, early graft function; DGF, delayed graft function; HLA, human leukocyte antigen. Values are expressed as mean±SD. P-value calculated by T-test and
Chi-square test.
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(>90% PBMC were viable).
RNA extraction and gene expression profiling
For all patients included in the training-group, total RNA
was extracted from 106 PBMCs at T0 and T24 using the
RNeasy Mini Kit (Qiagen AG, Basel, Switzerland). The
concentration of total RNA was measured using NANO-
DROP® spectrophotometer ND-1000 (Thermo Scientific,
Waltham, MA).
From all the 14 patients included in the training-
group, RNA was processed and hybridized to a set of 14
arrays for the “T0 analysis” and other 14 arrays for “T24
analysis”. For our experiments we used the GeneChip®
Human Genome U133A oligonucleotide microarray
(Affymetrix, Santa Clara, CA) which contains 22,283
gene probe sets, representing 12,357 human genes, plus
approximately 3,800 expressed sequence tag clones
(ESTs), according to manufacturer’s instructions. We
used the default settings of Affymetrix Microarray Suite
software version 5 (MAS 5.0; Affymetrix) to calculate
scaled gene expression values.
Confocal microscopy
In order to analyze the activation of karyopherin-related
machinery in DGF, we stimulated PBMCs with IL-6, a
major activator of signal transducer. In particular, by
binding its receptor IL6ST (GP130) and activating Janus
kinases (JAK), it induces the phosphorylation and activa-
tion of STATs (signal transducer and activator of tran-
scription), including STAT3 which then translocate to
the nucleus and act on target gene transcription. This
translocation is mediated by karyopherins-alpha.
Co-localization of KPNA (SRP) and either phospho-
STAT3 or total STAT3 was evaluated by indirect immuno-
fluorescence and confocal microscopy on PBMC isolated
from 5 DGF and 5 EGF (testing-group), incubated with
or without 50 ng/mL rh-IL-6 (Strathmann Biotec AG,
Hamburg, Germany) for 2 min and 5 min, and spotted onpoly-L-lysine-coated slides. We chose these two time
points and this concentration after time-course and dose–
response experiments (data not shown).
After fixing in 3.7% paraformaldehyde, cells were
permeabilized in PBS with 0.25% TritonX-100 for 7 min,
washed in PBS and then blocked with 2% bovine serum
albumin (BSA) in PBS for 1 hour at room temperature.
After blocking, the slides were incubated overnight with
anti-phospho-STAT3 (1:100, mouse anti–human mono-
clonal sc-8059, Santa Cruz Biotechnology, Santa Cruz,
CA) or anti-STAT3 antibody (1:100, rabbit anti-human
polyclonal sc-482, Santa Cruz Biotechnology). The slides
were then extensively washed in PBS and incubated
with Alexa Fluor goat anti-mouse 488 (1:200, Molecular
Probes, Eugene, OR) for 1 hour for double staining SRP/
phospho-STAT3 and with Alexa Fluor goat anti-rabbit
488 (1:200, Molecular Probes) for double staining SRP/
STAT3. After washings, the slides were blocked with BSA
2% for 1 hour and then incubated with anti-SRP antibody
(1:500, mouse polyclonal anti-human ab55387, Abcam,
Cambridge, UK). Sections were washed and then incu-
bated with Alexa Fluor goat anti-mouse 555 (1:200,
Molecular Probes). The nuclei were counterstained with
To-pro-3 (Molecular Probes). The slides were finally
mounted with GEL/MOUNT (Biomeda Corp., Foster
City, CA). Negative controls were performed by omitting
the primary antibodies. Fluorescence was acquired by a
Leica TCS SP2 (Leica, Wetzlar, Germany) confocal laser-
scanning microscope.
Statistical analysis
Data are expressed as the mean ± standard deviation
(SD). T-test and chi-square test were used to assess dif-
ferences in clinical and demographic features. A value of
p < 0.05 was considered to be statistically significant.
For microarray analysis, gene expression values for the
22,283 gene probe sets, scaled to the target intensity of
2,500, were log transformed. To identify significant tran-
scriptomic differences between DGF and EGF patients
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backs associated with standard approaches based on single
gene analysis [21], we used Gene Set Enrichment Analysis
(GSEA) [22], a statistically well founded method which
finds pathways and biological processes enriched of diffe-
rentially expressed genes in two different phenotypic con-
ditions. GSEA is a computational method that determines
in silico whether a group of genes included in the same
biological process (pathway) shows statistically significant
differences between two biological conditions (pheno-
types). This method uses a variation of a Kolmogorov-
Smirnov statistic to provide an enrichment score for each
gene set. We use the signal-to-noise metric in the stan-
dard GSEA setting as our score. These enrichment scores
are then normalized to take into account the size of the
gene sets resulting in a normalized enrichment score. We
performed 1000 random permutations of the phenotypic
labels to compute p-value and false discovery rate (FDR).
For our analysis, we used the global expression level of
825 biological processes listed in the c5 collection of Mo-
lecular Signature Database (MSigDB) (http://www.broad-
institute.org/gsea/msigdb/index.jsp) and the algorithm of
analysis described by Subramanian et al. [22]. R 2.0.1 sta-
tistical software was used to perform the above analyses.
Principal component analysis (PCA) was performed using
Spotfire Decision Site 9.0 (www.spotfire.com).
Results
Demographic and clinical characteristics
As shown in Table 1, we did not find any significant dif-
ference between DGF and EGF patients in several demo-
graphic and clinical parameters (donor and recipient age,
gender, number of HLA mismatch) in both training- and
testing-group. Only the cold-ischemia time resulted sig-
nificantly higher in DGF compared to EGF (p < 0.05) in
both study groups. The length of DGF was 17.8 ± 12.8 and
14.2 ± 16.3 days (mean ± SD) in training- and testing-
group, respectively.
Identification of a specific pre-transplant transcriptomic
fingerprint associated with DGF
In order to identify a pre-transplant (T0) PBMCs’ tran-
scriptomic profiling associated with DGF, we compared
the expression level of 825 pathways in DGF versus EGF
patients.
After statistical analysis/bioinformatics, 15 pathways re-
sulted differentially expressed in DGF versus EGF patients
at T0 (p < 0.001, False Discovery Rate < 10%) (Table 2).
In particular 8 pathways resulted up-regulated (NLS
bearing substrate import into nucleus, nuclear transport,
nucleocytoplasmic transport, protein import into nucleus,
ribonucleotide metabolic process, nuclear import, pyrimi-
dine nucleotide metabolic process, macromolecule loca-
lization), while 7 down-regulated in DGF (Vasculaturedevelopment, activation of protein kinase activity, regula-
tion of angiogenesis, G protein signaling coupled to IP3
phospholipase c activating, phosphoinositide mediated sig-
naling, phospholipase c activation, regulation of myeloid
cell differentiation) compared to EGF.
NLS-bearing substrate import into nucleus was the
most significantly up-regulated pathway in DGF at T0
(p < 0.001). This pathway included genes encoding for
several isoforms of karyopherins, a group of proteins
mainly involved in the nucleocytoplasmic transport.
Identification of DGF-related transcriptomic profiling
24 hours after transplantation
The same statistical strategy used for the microarray ana-
lysis at T0 was used to identify pathways differentially
expressed in PBMCs isolated at T24 in 7 DGF versus 7
EGF patients.
Bioinformatics revealed that 24 hours after renal trans-
plantation, 5 pathways resulted up-regulated (NLS bearing
substrate import into nucleus, regulation of small GTPase
mediated signal transduction, RNA 3 end processing, regu-
lation of ras protein signal transduction and protein import
into nucleus) and 6 down-regulated (positive regulation of
epithelial cell proliferation, rhythmic process, negative regu-
lation of translation, keratinocyte differentiation, negative
regulation of cytokine biosynthetic process, negative regula-
tion of biosynthetic process) in DGF compared to EGF (p <
0.001, False Discovery Rate < 10%) (Table 3).
Interestingly, also at T24, the top discriminating path-
way between DGF versus EGF was NLS-bearing sub-
strate import into nucleus (p < 0.001) (Tables 2 and 3).
Three-dimensional discrimination of DGF from EGF
according to NLS-bearing substrate import into nucleus
pathway
Principal component analysis using the expression level
of all 13 genes included in the NLS-bearing substrate im-
port into nucleus pathway was able to clearly discrimin-
ate in three dimensional space DGF from EGF at both
T0 (Figure 1A) and T24 (Figure 1B).
Pre-transplant karyopherins-alpha mediated pSTAT3
nuclear migration
To confirm a possible activation of the karyopherin-
related machinery in DGF, we analyzed the migration of
pSTAT3 from the cytoplasm into the nucleus in PBMCs
isolated at T0 from 5 DGF and 5 EGF patients (testing-
group) after a short induction (2 and 5 minutes) with
IL-6, a well known inducer of this migration process.
The ratio of pSTAT3/STAT3 in PBMCs was signifi-
cantly higher in in unstimulated cells of DGF compared
to EGF patients (more than 10 folds comparing basal
levels).
Table 2 Pathways discriminating patients developing delayed graft function (DGF) from those having early graft
function (EGF) at the time of transplantation (T0)
Pathway Number
of genes
Gene symbol p value
UP-REGULATED IN DGF
NLS bearing substrate import into nucleus 13 CBLB, FYB, KPNA1, KPNA2, KPNA3, KPNA4, KPNA5, KPNA6, KPNB1, NCKIPSD,
RANBP5, RERE, TRPS1
<0.001
Nuclear transport 89 AKT1, ALS2CR2, ANP32A, ATXN1, BARD1, BAT1, BCL3, BCL6, CALR, CBLB, CDH1,
DDX19B, DDX25, DDX39, DUSP16, EIF5A, F2, F2R, FAF1, FLNA, FYB, GLI3, GSK3B,
HNRNPA1, HRB, HTATIP2, KHDRBS1, KPNA1, KPNA2, KPNA3, KPNA4, KPNA5, KPNA6,
KPNB1, LYK5, MALT1, MCM3AP, MDFI, MXI1, MYBBP1A, NCBP2, NCKIPSD, NF1,
NFKBIE, NFKBIL1, NFKBIL2, NLRP12, NLRP3, NOP5/NOP58, NPM1, NUDT4, NUP107,
NUP133, NUP160, NUP205, NUP214, NUP98, NUPL2, NXF5PDIA3, PPIH, PPP1R10,
PTTG1IP, RAE1, RANBP2, RANBP5, RERE, RPAIN, SMAD3, SMG1, SMG5, SMG6, SMG7,
TBRG1, TGFB1, TNF, TNFSF14, TNPO1, TPR, TRIP6, TRPS1, TSC1, UHMK1, UPF1,
UPF2, XPO6, XPO7, ZFYVE9
0.004
Nucleocytoplasmic transport 88 AKT1, ALS2CR2, ANP32A, ATXN1, BARD1, BAT1, BCL3, BCL6, CALR, CBLB, CDH1,
DDX19B, DDX25, DDX39, DUSP16, EIF5A, F2, F2R, FAF1, FLNA, FYB, GLI3, GSK3B,
HNRNPA1, HRB, HTATIP2, KHDRBS1, KPNA1, KPNA2, KPNA3, KPNA4, KPNA5, KPNA6,
KPNB1, LYK5, MALT1, MCM3AP, MDFI, MXI1, MYBBP1A, NCBP2, NCKIPSD, NF1,
NFKBIE, NFKBIL1, NFKBIL2, NLRP12, NLRP3, NOP5/NOP58, NPM1, NUDT4, NUP107,
NUP133, NUP160, NUP205, NUP214, NUP98, NUPL2, NXF5PDIA3, PPIH, PPP1R10,
PTTG1IP, RAE1, RANBP2, RANBP5, RERE, RPAIN, SMAD3, SMG1, SMG5, SMG6, SMG7,
TGFB1, TNF, TNFSF14, TNPO1, TPR, TRIP6, TRPS1, TSC1, UHMK1, UPF1, UPF2, XPO6,
XPO7, ZFYVE9
0.004
Protein import into nucleus 48 AKT1, BCL3, BCL6, CBLB, CDH1, CEP57, F2, F2R, FAF1, FLNA, FYB, GLI3, KPNA1,
KPNA2, KPNA3, KPNA4, KPNA5, KPNA6, KPNB1, MCM3AP, MDFI, MXI1, NCKIPSD,
NF1, NFKBIE, NFKBIL1, NFKBIL2, NLRP12, NLRP3, NOP5/NOP58, NUP205, PDIA3,
PPIH, PPP1R10, PTTG1IP, RANBP2, RANBP5, RERE, RPAIN, SMAD3, TGFB1, TNF,
TNFSF14, TNPO1, TPR, TRIP6, TRPS1, ZFYVE9
0.004
Ribonucleotide metabolic process 16 ACLY, ADK, ADSS, AK5, AMPD3, C16orf7, CMPK, CTNS, CTPS, ENTPD4, FIGNL1,
GUK1, NDUFS1, NUDT5, OLA1, UMPS
0.004
Nuclear import 50 AKT1, BCL3, BCL6, CBLB, CDH1, CEP57, F2, F2R, FAF1, FLNA, FYB, GLI3, HNRNPA1,
HTATIP2, KPNA1, KPNA2, KPNA3, KPNA4, KPNA5, KPNA6, KPNB1, MCM3AP, MDFI,
MXI1, NCKIPSD, NF1, NFKBIE, NFKBIL1, NFKBIL2, NLRP12, NLRP3, NOP5/NOP58,
NUP205, PDIA3, PPIH, PPP1R10, PTTG1IP, RANBP2, RANBP5, RERE, RPAIN, SMAD3,
TGFB1, TNF, TNFSF14, TNPO1, TPR, TRIP6, TRPS1, ZFYVE9
0.006
Pyrimidine nucleotide metabolic process 10 AK5, CMPK, CTPS, DCK, DCTD, ENTPD4, NT5C, NT5M, TYMP, UMPS 0.006
Macromolecule localization 237 ABCA1, ABCG1, ACHE, AGXT, AIP, AKAP10, AKT1, ALS2CR2, ANG, ANGPTL3, AP1G1,
AP1GBP1, AP1M2, AP3B1, AP3D1, AP3M1, AP3S2, APBA1, APOA1, APOA2, APPBP2,
ARCN1, ARFGAP3, ARFIP1, ARL4D, ATG4A, ATG4B, ATG4C, ATG4D, BACE2, BARD1,
BAT1, BCL3, BCL6, BIN3, BIRC5, C3orf31, CADM1, CALR, CANX, CARD8, CBLB, CBY1,
CD24, CD3G, CD74, CD81, CDC37, CDH1, CEP290, CEP57, CIDEA, CKAP5, COG2,
COG3, COG7, COLQ, COX18, CRTAM, CTSA, CUTA, DDX19B, DDX25, DDX39,
DERL1, DERL2, DNAJC1, DPH3, DUSP16, EGFR, EIF5A, ERCC3, ERP29, F2, F2R, FAF1,
FLNA, FOXP3, FYB, GABARAP, GGA1, GGN, GLI3, GLMN, GSK3B, HNRNPA2B1,
HOMER3, HPS4, HRB, ICMT, INS, KDELR1, KDELR2, KHDRBS1, KIF13B, KLHL2, KPNA1,
KPNA2, KPNA3, KPNA4, KPNA5, KPNA6, KPNB1, LGTN, LMAN2L, LRP1B, LTBP2,
LYK5, MAL, MCM3AP, MDFI, MFN2, MIPEP, MXI1, MYH9, MYO6, NAGPA, NCBP2,
NCKIPSD, NF1, NFKBIE, NFKBIL1, NFKBIL2, NLGN1, NLRC4, NLRP12, NLRP2, NLRP3,
NOD2, NOP5/NOP58, NPM1, NUDT4, NUP107, NUP133, NUP160, NUP205, NUP214,
NUPL2, NXF5, OPTN, PDIA2, PDIA3, PDIA4, PEX1, PEX10, PEX12, PEX13, PEX14,
PEX16, PEX19, PEX26, PEX3, PEX6, PEX7, PPIH, PPP1R10, PPT1, PPY, PTTG1IP,
PYCARD, PYDC1, RAB35, RAB3GAP2, RAE1, RANBP2, RANBP5, REEP1, RERE, RPAIN,
RPGR, RPL11, RTP1, RTP2, RTP3, RTP4, SCG2, SCG5, SEC23IP, SEC63, SELS, SERGEF,
SHROOM2, SHR
0.008
DOWN-REGULATED IN DGF
Vasculature development 55 ACVRL1, AGGF1, AMOT, ANG, ANGPTL3, ANGPTL4, ATPIF1, BTG1, C1GALT1, CANX,
CCM2, CDH13, CHRNA7, COL4A2, COL4A3, CUL7, EGF, EGFL7, EMCN, EPGN, ERAP1,
FOXC2, FOXO4, GLMN, HTATIP2, IL17F, IL18, IL8, MYH9, NCL, NF1, NOTCH4, NPPB,
NPR1, PDPN, PF4, PLG, PML, PROK2, RASA1, RHOB, RNH1, ROBO4, RUNX1, SCG2,
SERPINF1, SHH, SPHK1, SPINK5, STAB1, TGFB2, THY1, TNFSF12, TNNI3, VEGFA
0.005
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Table 2 Pathways discriminating patients developing delayed graft function (DGF) from those having early graft
function (EGF) at the time of transplantation (T0) (Continued)
Activation of protein kinase activity 28 ALS2CR2, ANG, AZU1, CARD10, CARTPT, CCDC88A, CHRM1, EDN2, GADD45B,
GADD45G, GAP43, IRAK1, LYK5, MALT1, MAP3K13, MAP3K4, MAP3K7, MAP3K7IP1,
PARD3, PICK1, PPAP2A, PRKD3, TAOK2, TNFSF15, TRAF2, TRAF6, TRAF7, ZAK
0.006
Regulation of angiogenesis 26 AGGF1, AMOT, ANGPTL3, ANGPTL4, BTG1, CHRNA7, COL4A2, COL4A3, FOXO4,
HTATIP2, IL17F, NF1, NPPB, NPR1, PF4, PLG, PML, RHOB, RNH1, RUNX1, SERPINF1,
SPHK1, SPINK5, STAB1, TNFSF12, TNNI3
0.006
G PROTEIN Signaling coupled to IP3
phospholipase C activating
45 AGTR1, ANG, AVPR1A, AVPR1B, AZU1, C5AR1, CALCA, CCKAR, CCKBR, CHRM1,
CHRM2, DRD1, DRD2, EDG2, EDG4, EDG6, EDN2, EDNRA, EDNRB, EGFR, F2RL3,
GAP43, GNA15, GNAQ, GRM5, HOMER1, HRH1, HTR2B, IL8RB, LTB4R, MC3R, NMBR,
NMUR1, NMUR2, P2RY1, P2RY11, P2RY2, P2RY4, P2RY6, PARD3, PICK1, PLCB2,
PPAP2A, PRKD3, TACR1
0.007
Phosphoinositide mediated signaling 48 AGTR1, ANG, AVPR1A, AVPR1B, AZU1, C5AR1, CALCA, CCKAR, CCKBR, CHRM1,
CHRM2, DRD1, DRD2, EDG2, EDG4, EDG6, EDN2, EDNRA, EDNRB, EGFR, F2RL3,
GAP43, GNA15, GNAQ, GRM5, HOMER1, HRH1, HTR2B, IL8RB, LTB4R, MC3R, NMBR,
NMUR1, NMUR2, P2RY1, P2RY11, P2RY2, P2RY4, P2RY6, PARD3, PICK1, PLCB2,
PLCE1, PLCH1, PPAP2A, PRKD3, PTAFR, TACR1
0.007
Phospholipase C activation 14 ANG, AVPR1A, AVPR1B, C5AR1, CCKBR, EDG2, EDG4, EDG6, EDNRA, EGFR, GNA15,
GNAQ, NMUR1, PLCB2
0.008
Regulation of myeloid cell differentiation 19 ACIN1, ACVR1B, ACVR2A, CALCA, CARTPT, CDK6, ETS1, FOXO3, IL4, INHA, INHBA,
LDB1, MAFB, PF4, RUNX1, SCIN, SPI1, ZBTB16, ZNF675
0.009
P value, calculated by using an empirical phenotype-based permutation test procedure, represents the degree to which the pathway is over-represented at the
extremes (top or bottom) of the entire ranked list of the total 825 pathways analyzed after comparison DGF versus EGF (for details about the statistical
methodology see Subramanian et al. [22]).
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STAT3 ratio increased rapidly in DGF after short stimu-
lation with IL-6 (Figure 2A and C). On the contrary, in
PBMCs isolated from EGF patients, the IL-6 did not in-
duce the aforementioned changes (Figure 2B and C).
Therefore, these findings suggest that the karyopherin-
mediated shuttling of intracellular molecules (e.g., tran-
scription factors) may play a role in the onset of DGF in
renal transplant patients. However additional studies are
needed to confirm and to better address this point.
Discussion
DGF represents not only the need for continued dialysis,
but it is strongly associated with both acute rejection and
decreased graft survival [23,24]. In particular, in the long
term, patients with DGF are 1.53 times more susceptible
to graft loss at 5 years and have an overall 10% lower graft
survival rate compared to EGF patients [23-26].
Because of the negative impact of DGF on periope-
rative care and graft outcome, great efforts have been
made to understand the pathogenesis and the biological
factors associated with this clinical condition.
Moreover, a variety of clinical algorithms and biological
elements have been proposed to predict DGF based on
pre-operative risk factors [27-32], but, at the moment, no
suitable biomarkers have successfully entered in routine
clinical practice.
Additionally, it is unquestionable that, because of a
large number of biological factors involved, we are still
far from the comprehension of the personal risk factors
predisposing to this important clinical complication.Therefore, it is reasonable that the knowledge of a
new piece in the puzzle of DGF could help researchers
to identify new potential early diagnostic biomarkers and
therapeutic target.
To this purpose, we decided to apply a new analytic
microarray strategy to identify biological pathways in-
volved in development of DGF. We chose this new me-
thodological approach because an initial classical “gene by
gene” analysis, revealed only weak differences between
DGF versus EGF at both T0 and T24. This could be due
to the low number of patients included in our study. In
fact, other studies utilizing a large dataset, have identified
several potential predictive DGF biomarkers with a clas-
sical microarray analysis [32,33]. The main property of
GSEA is that it finds significant pathways related to the
analyzed phenotypic differences by integrating weak asso-
ciation signals that would be lost due to the huge amount
of assayed genes. The significance of a pathway was as-
sessed through non-parametric permutation tests that
compare the actual normalized enrichment score with the
ones obtained by chance. To this end, 1000 random per-
mutations of the phenotypic labels were performed. In the
permutation tests the enrichment scores were properly
normalized in order to consider the size of the pathways.
Moreover, the effects of the multiple comparisons were
taken into account by assessing for each pathway the false
discovery rate.
However, when we used a customized pathway ana-
lysis, we identified 15 pathways (8 up-regulated and 7
down-regulated) and 11 pathways (5 up-regulated and 6
down-regulated) significantly associated with DGF at T0
Table 3 Pathways discriminating patients developing delayed graft function (DGF) from those having early graft
function (EGF) 24 hours after transplantation (T24)
Pathway Number
of genes
Gene symbol p value
UP-REGULATED IN DGF
NLS bearing substrate import into nucleus 13 CBLB, FYB, KPNA1, KPNA2, KPNA3, KPNA4, KPNA5, KPNA6, KPNB1,
NCKIPSD, RANBP5, RERE, TRPS1
<0.001
Regulation of small GTpase mediated signal transduction 24 ABRA, ALS2, ARF6, ARHGAP27, CDC42BPA, CDC42BPB, CDC42BPG,
CENTD2, CENTD3, DMPK, FGD1, FGD2, FGD3, FGD4, FGD5, FGD6,
MFN2, NF1, NOTCH2, PLCE1, RAC1, RALBP1, RASGRP4, TSC1
0.005
RNA 3 end processing 10 CPSF1, CPSF3, CSTF1, CSTF2, CSTF3, GRSF1, NCBP1, PABPC1, SLBP,
TRNT1
0.006
Regulation of RAS protein signal transduction 19 ABRA, ALS2, ARF6, ARHGAP27, CENTD2, CENTD3, FGD1, FGD2,
FGD3, FGD4, FGD5, FGD6, MFN2, NF1, NOTCH2, PLCE1, RAC1,
RALBP1, RASGRP4, TSC1
0.009
Protein import into nucleus 48 AKT1, BCL3, BCL6, CBLB, CDH1, CEP57, F2, F2R, FAF1, FLNA, FYB,
GLI3, KPNA1, KPNA2, KPNA3, KPNA4, KPNA5, KPNA6, KPNB1,
MCM3AP, MDFI, MXI1, NCKIPSD, NF1, NFKBIE, NFKBIL1, NFKBIL2,
NLRP12, NLRP3, NOP5/NOP58, NUP205, PDIA3, PPIH, PPP1R10,
PTTG1IP, RANBP2, RANBP5, RERE, RPAIN, SMAD3, TGFB1, TNF,
TNFSF14, TNPO1, TPR, TRIP6, TRPS1, ZFYVE9
0.009
DOWN-REGULATED IN DGF
Positive regulation of epithelial cell proliferation 10 EGFR, EPGN, ERBB2, FGF10, LAMA1, LAMB1, LAMC1, NME1, NME2,
TGFA
0.003
Rhythmic process 29 AANAT, ARNTL, BMPR1B, CARTPT, CLOCK, CRY1, EGR3, EIF2B2,
EIF2B4, EIF2B5, ENOX2, EREG, FOXL2, HEBP1, HTR7, MTNR1A, OPN4,
PER1, PER2, PTGDS, SOD1, SPRR2A, SPRR2B, SPRR2C, SPRR2D,
SPRR2E, SPRR2F, SPRR2G, TIMELESS
0.004
Negative regulation of translation 23 APBB1, BCL3, EIF2AK1, EIF2AK3, EIF4A3, ELA2, FOXP3, FURIN, GHRL,
GHSR, IL10, IL6, INHA, INHBA, INHBB, NDUFA13, NLRP12, PAIP2,
PAIP2B, PRG3, SFTPD, SIGIRR, TSC1
0.006
Keratinocyte differentiation 15 ANXA1, CSTA, DSP, EREG, EVPL, IL20, IVL, LOR, NME2, SCEL, SPRR1A,
SPRR1B, TGM1, TGM3, TXNIP
0.006
Negative regulation of cytokine biosynthetic process 12 BCL3, ELA2, FOXP3, GHRL, GHSR, IL6, INHA, INHBA, INHBB, NLRP12,
SFTPD, SIGIRR
0.008
Negative regulation of biosynthetic process 30 APBB1, BACE2, BCL3, BRCA1, EIF2AK1, EIF2AK3, EIF4A3, ELA2,
FOXP3, FURIN, GCK, GHRL, GHSR, GLA, GRM8, IL10, IL6, INHA,
INHBA, INHBB, NDUFA13, NLRP12, PAIP2, PAIP2B, PDZD3, PRG3,
SFTPD, SIGIRR, SOD1, TSC1
0.009
P value, calculated by using an empirical phenotype-based permutation test procedure, represents the degree to which the pathway is over-represented at the extremes
(top or bottom) of the entire ranked list of the total 825 pathways analyzed after comparison DGF versus EGF (for details about the statistical methodology see
Subramanian et al. [22]).
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known to be deregulated in DGF patients have been iden-
tified. Only the IL-18, was included in one of the deregu-
lated pathways in DGF at T0 (vasculature development).
This result could be due to the fact that our analysis has
been performed on RNA extracted from PBMC. In fact,
these markers have been primarily studied in urine and
tissue samples.
Interestingly, the most significantly up-regulated path-
way at both time points was the NLS-bearing substrate
import into nucleus. This pathway is involved in the
movement of a protein bearing a nuclear localization
signal (NLS) from the cytoplasm into the nucleus, across
the nuclear membrane.In detail, this nucleocytoplasmic transport occurs through
cylindrical structures spanning the nuclear envelope known
as nuclear pore complexes (NPCs) [34]. NPCs are large
protein assemblies of approximately 125 MDa in mamma-
lian cells. These structures allow passive exchange of ions,
small molecules and small proteins (<20 KDa), but restrict
passage of macromolecules to only those bearing appro-
priate signals. The direction of transport through the NPC
is determined by a signal. The NLS directs proteins into
the nucleus and the nuclear export signal (NES) directs
the transport of proteins toward the cytoplasm.
Karyopherin-alpha (also known as importin-alpha) is an
adaptor protein that recognizes the first discovered or clas-
sical NLS, which is characterized by one or two stretches
Figure 1 Principal components analysis (PCA) discriminating renal transplant patients with delayed graft function (DGF) from early
graft function (EGF) at the time of transplantation (T0) (A) and 24 hours after transplantation (T24) (B) using the expression level of
the genes included in the NLS-bearing substrate import into nucleus pathway. Both PCA plots were built using the expression level of all
13 genes included in the NLS-bearing substrate import into nucleus pathway. Red dots indicate patients that developed DGF after transplantation
and green dots those with EGF. PCA clearly discriminated in three dimensional space the two study groups at both time points.
Figure 2 Phospho-STAT3 (pSTAT3) karyopherins-related nuclear translocation in peripheral blood mononuclear cells (PBMCs) of 5
patients with delayed graft function (DGF) and 5 with early graft function (EGF) after short stimulation with Interleukin (IL)-6. (A and B)
Histograms represent the pSTAT3/STAT3 ratio after 2 and 5 minutes of IL-6 stimulation in PBMCs isolated from 5 DGF and 5 EGF patients, respectively;
(C) Panels report a representative experiment of the nuclear translocation of p-STAT3 in PBMCs of DGF (upper) and EGF (lower) in basal conditions and
after 2 and 5 minutes of IL-6 stimulation. (*) p-value versus basal.
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interacts with Karyopherin-beta1 (also known as importin-
beta) and together these proteins form a heterodimer
which mediates the nuclear import of proteins containing
a classical NLS [35]. Our data underlines that our cells
show the activation of this machinery.
Previous research showed that members of the signal
transducers family and activators of transcription (STAT)
use this mechanism for their passage from cytoplasm into
the nucleus [37-43]. These molecules, and in particular
those involved in the JAK/STAT signaling are primarily in-
volved in the pathogenesis of renal I/R injury [44-47].
Therefore, although there are some limitations (such as
small number of patients included in the microarray ana-
lysis, absence of the analysis of the predictive power of our
identified biological elements and absence of graft histo-
logical evaluation) our study shows, for the first time, that
karyopherins may have a pivotal role in the development
of DGF and these molecules may be new valuable diag-
nostic predictors. Additionally, they could in future be
used as therapeutic targets. In fact, in the last years,
several drugs have been studied acting inhibiting karyo-
pherin trafficking (e.g., importazole, Ivermectin) [48-50].
Conclusions
In conclusion, the present study, utilizing an innovative
transcriptomic approach, suggests the involvement, imme-
diately before transplantation, of karyopherin-mediated
nuclear transport in the onset and development of DGF.
Additionally, although further studies are needed, it re-
veals that the analysis of this condition could represent a
new potential clinical tool useful as predictive and early
diagnostic DGF biomarker in renal transplantation.
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